TRxADE GROUP, INC. Launches New Enhancements to Trading Platform

TRxADE GROUP, INC. Launches New Enhancements to Trading Platform

SOURCE: Trxade Group, Inc.

Press Release | 10/02/2018

TAMPA, FL / ACCESSWIRE / October 2, 2018 / Trxade Group, Inc., (OTCQB: TRXD) a web-based market platform with 9,300 registered independent pharmacy customers that enables its customers to quickly source and purchase pharmaceuticals, accessories and services from a wide range of manufacturers and drug distributors today announced new enhancements to the trading platform.

Jariel Morales, Executive Vice President of Trxade Group said, “As we continue on our path of being a premier healthcare solutions provider, our team has focused on the voice of the customer and expanding our portfolio to provide additional services to our members that increase their bottom line revenue, increase the number of patients they see each month, and provide alternative health solutions to their patient base. By focusing on the voice of the customer and their direct needs, we experienced record-breaking figures this quarter where we experienced a record-breaking number of buyers, orders per day, and line items/products sold per day. We look forward to meeting the demands of our members and continuing to see the growth we are experiencing through the 4th quarter.”

Launched Trxade Release Version 1.17 on our Nova platform.

  • New and advanced filters allowing members to select VAWD, VAWD Pending, or Non-VAWD Suppliers and filter their favorite products by Brand or Generic.
  • We continuously focus on making it easier to find significant savings on products for our Pharmacy members and this release helps meet that goal. We launched recommended products at the shopping cart level to help our Pharmacy members meet the minimum per order required via data analytics. This feature informs them of products their peers are procuring through the platform by each supplier including auto selecting the preferred method of shipping.
  • We are proud to announce that this release also features our updated dashboard displaying additional product lines trending including Vials, Test Strips, Alcohol Pads, Syringes, and other categories our members report significant savings versus their primary wholesalers. The new updated Dashboard also focuses on Trending items tied to an algorithm which features artificial intelligence to provide the best priced products to each member based on buying patterns yielding a maximum significant time and cost savings.
  • “Do Not Contact” feature has been implemented allowing our Pharmacies to request marketing “opt-out” from up to 45 wholesalers with just one click.
  • We have also incorporated Orange Book ratings for Rx products, as well as Unit of Measure on each package size.
  • New updated Dashboard that focuses on Trending items tied to an algorithm featuring artificial intelligence providing best priced products to each member based off buying patterns yielding a significant time and cost savings.

About Trxade Group, Inc.

Headquartered in Tampa, Florida, Trxade Group, Inc. (OTCQB: TRXD) is a web-based market platform that enables trade among healthcare buyers and sellers of pharmaceuticals, accessories and services. Founded in 2010, Trxade Group currently operates the trading platform with 9,300 registered members. For additional information please visit us at http://www.trxadegroup.com.

Forward-Looking Statements

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. Except as may be required by applicable law, we assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The company undertakes no duty to update forward-looking statements.

Investor Relations Contact:

Christi Justi
1-800-261-0281

Reduce Drug Pricing

Senators to Trump: Reduce Drug Pricing

Senators Ask President-Elect Trump to Reduce Drug Pricing

In a letter dated December 20, 2016, Senators Sherrod Brown (D-OH) and Al Franken (D-MN) asked President-elect Trump to help lawmakers bring down prescription drug prices. The letter was co-signed by 18 other senators, including Bernie Sanders (D-VT) and Elizabeth Warren (D-MA).

The letter to President-Elect Trump begins, “During your campaign, you promised to implement bold reforms to bring down the cost of prescription drugs. In fact, you acknowledged that ‘Congress will need the courage to step away from the special interests and do what is right for America’.” The letter goes on the say that Trump supported allowing consumers’ access to imported, safe, and dependable drugs from overseas and vowed to negotiate lower prescription drug prices for seniors.

The letter also states that drug companies often engage in abusive tactics that price lifesaving drugs out of reach for those in need. The Senators tell Trump that it is time to enact policies that improve transparency and competition in the commercial market and make the government a smarter purchaser of prescription drugs. (Hey, Trxade advocates for transparency, competition, and smarter pharma purchases, too!)

The letter continues with the following five administrative and legislative actions (the letter details each one) that Trump can take in partnership with both parties in Congress:
1. Give the Secretary of HHS the authority to negotiate drug prices
2. Increase transparency
3. Stop abusive pricing
4. Protect and incentivize true innovation
5. Ensure true competition

The letter concludes by asking Trump to prioritize prescription drug pricing reform while in office.

Click here to read the full letter, complete with the Senators’ signatures:
Letter

Trxade Group, Inc. Reports Second Quarter 2016 Financial Results

Company Expects Accelerated Growth Ahead

| Source: Trxade Group, Inc.

Second Quarter Highlights:
  • Second quarter 2016 revenues increased 45% from same period in 2015
  • Number of S2P independent pharmacies continues to expand, now over 5,860
  • Company has launched Gabapentin tablets in second quarter 2016
  • Expects fast track growth through private label pharmaceuticals

TAMPA, Fla., Aug. 08, 2016 (GLOBE NEWSWIRE) — Trxade Group, Inc., (OTCQB:TRXD), a web-based market platform enabling its independent pharmacy customers to quickly source pharmaceuticals, accessories and services from a wide range of manufacturers and distributors today reported record financial results for its second quarter ended June 30, 2016.

Company Achieves Record Second Quarter Financial Results

Revenues for the three months ended June 30, 2016 increased 45% to a record $1,688,990, compared with $1,167,195 for the same period in 2015. The increase in revenues for 2016 was primarily due to increased sales from the Company’s wholesale pharmaceutical division.

Cost of sales in the quarter increased to $1,039,889 compared to $382,004 in the year-ago quarter. This increase was primarily attributable to an increase in pharmaceutical sales, which has a higher cost of sales than the Company’s other revenue sources. Gross profit for the three-month period ended June 30, 2016 was $649,101 compared with $785,191 a year ago.

The net operating loss for the three-month period ended June 30, 2016 and 2015 was ($1,013,394) and ($26,448), respectively. The increase is attributable to initial infrastructure expenses for the Company’s private label pharmaceutical distribution.

Company CEO Sees Accelerated Growth in Coming Quarters

Commenting on the Company’s record second quarter results, Suren Ajjarapu Trxade Group Chairman and Chief Executive officer, said, “We are pleased with the significant progress we achieved during the second quarter of 2016. Launching new private label products and crossing 5,800 registered pharmacies on our S2P platform was a major milestone for our company. We are encouraged by the early feedback received from our network of independent pharmacies using the Trxade Prime platform. These services are producing significant cost savings for our network pharmacies and will continue to be one of the driving forces for the adoption of our services as our network pharmacies continues to expand.

“We enter the third quarter of 2016 well positioned across our products from a marketing, online experience and private label distribution standpoint. We expect significant growth in our private label distribution to continue, which will be the key to the success of our business strategy moving forward. We remain focused on our execution and expect accelerating growth and a clear path towards profitability in the coming quarters,” Mr. Ajjarapu concluded.

About Trxade Group, Inc.

Headquartered in Tampa, Florida, Trxade Group, Inc. (OTCQB:TRXD) is a web based market platform that enables trade among healthcare buyers and sellers of pharmaceuticals, accessories and services.  Founded in 2010, Trxade Group currently operates the trading platform with over 5860 registered independent pharmacy members. Trxade Group also distributes private label pharmaceuticals through their 100% subsidiary Westminster Pharmaceuticals. For additional information please visit us at http://www.trxadegroup.com.

Forward-Looking Statements

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements.  Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. Except as may be required by applicable law, we assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.  The company undertakes no duty to update forward-looking statements.

(Financial Tables to Follow)

Trxade Group, Inc.
Consolidated Statements of Operations
Three months and six months ended June 30, 2016 and 2015
(unaudited)
Three months ended Six months ended
 2016  2015  2016  2015
Revenues $   1,688,990 $   1,167,195 $   3,536,141 $   1,863,328
Cost of Sales   1,039,889   382,004   2,055,971   612,467
Gross Profit   649,101   785,191   1,480,170   1,250,861
Operating Expenses
General and Administrative   1,662,495   811,639   2,803,311   1,719,960
Operating Loss   (1,013,394 )   (26,448 )   (1,323,141 )   (469,099 )
Loss on Debt Extinguishment   37,579  –   37,579  –
Interest Expense   50,842   27,908   113,475   28,877
Net Loss $   (1,101,815 ) $   (54,356 ) $   (1,474,195 ) $   (497,976 )
Basic loss per Common Share $   (.04 ) $   (.00 ) $   (.05 ) $   (.02 )
Diluted loss per Common Share $   (.04 ) $  (.00 ) $   (.05 ) $   (.02 )
Basic weighted average number of Common Shares outstanding 31,468,245 31,269,160 31,468,245 31,269,160
Diluted weighted average number of Common Shares outstanding 31,468,245 31,269,160 31,468,245 31,269,160

 

Trxade Group, Inc.
Consolidated Balance Sheets
June 30, 2016 and December 31, 2015
(unaudited)
June 30, 2016 December 31, 2015
Current Assets
Cash $   319,588 $   860,132
Accounts Receivable, net   373,653   498,100
Inventory, net   538,757   284,718
Prepaid Net Assets   203,558   201,361
Other Assets  –   183,359
Total Current Assets   1,435,536   2,027,670
Total Assets $   1,435,536 $   2,027,670
  Liabilities and Shareholders’ Equity (Deficit)
Current Liabilities
Accounts Payable $   353,067 $   356,159
Accrued Liabilities   608,864   296,803
Promissory Note, net of $37,500 and $15,000 discount   212,500   235,000
Convertible Note, net of $0 and $35,697 discount   165,000   164,303
Total Current Liabilities   1,339,431   1,052,265
Long Term Liabilities
Convertible Note net of $256,273 and $241,612 discount   943,727   708,388
Total Liabilities   2,283,158   1,760,653
Shareholders’ Equity
Series A Preferred Stock, $.00001 par value, 10,000,000 authorized; 0 and 0 issued and outstanding, as of June 30, 2016 and December 31, 2015
Common Stock, $0.00001 par value; 100,000,000 shares authorized; 31,535,827 and 31,269,160 shares issued and outstanding, as of June 30, 2016 and December 31, 2015, respectively   315   314
Additional Paid-in Capital   6,275,229   5,915,674
Retained Earnings (Deficit)   (7,123,166 )   (5,648,971 )
Total Shareholders’ Equity (Deficit)   (847,622 )   267,017
Total Liabilities and Shareholders’ Equity (Deficit) $   1,435,536 $   2,027,670
Investor Relations Contact:
Phillip Sugarman, Vice President, Investor Relations
Phone: 818-280-6800
psugarman@irpartnersinc.com

John Hoffmire: What can be done to convince pharmaceutical firms to lower prescription drug prices?